BRIEF-Celldex Therapeutics up in premarket after CDX-011 phase 2 study results
NEW YORK Dec 10 (Reuters) - Celldex Therapeutics Inc : * Up 9.6 percent to $6.05 in premarket after CDX-011 phase 2 study results in patients with glycoprotein NMB (GPNMB)-expressing, advanced, heavily pretreated breast cancer
- Putin dissolves state news agency, tightens grip on Russia media
- North Korea says Kim's powerful uncle dismissed for 'criminal acts'
- Thai PM calls snap election, protesters want power now |
- Record cold, ice grip U.S.; snow heads East
- Protesters fell Lenin statue, tell Ukraine's president 'you're next'